Consortium members have the
Most Pipe-Lines, Biggest Manufacturing Sites, the Highest Research
capability and expenditure
Our currently running
mRNA vaccine programs
comprise of
- Consortium members own
- Through co-development match making programs
-
KHUB in-house developed leads from
many
research organizations worldwide
Two new autonomous, 100% in-house manufacturing sites in Korea at Local Government Special Industrial Zones are under constructions to complete the task of 5 Billion Doses mRNA vaccine supply to WHO's LMIC regions, Asia Pacific and beyond.
- 5
-
Billion Doses
mRNA vaccine supply
- 100
-
in-house
manufacturing sites
KHUB CONSORTIUM BUSINESS MODEL
is an "Infrastructure Service Provider" to help partners quickly realize the local immunization with "Pandemic-Expedited" developmental pathways. We always try to work with many national level research organizations for safer and better vaccine supplies that will bring economical answer to end pandemic globally.
